Fractyl Health, Inc. — Cyborg Score 5/10

Strategic Profile

Fractyl is positioned at the intersection of GLP-1 resistance and next-generation metabolic disease therapy. With pivotal trial data expected in H2 2026 and an FDA De Novo submission pathway, the company is advancing from clinical to commercial-stage operations while maintaining significant institutional backing and a cash runway into early 2027.

Cyborg Score Rationale

Strong clinical progress with positive REMAIN-1 midpoint data and clear regulatory pathway, offset by minimal revenue, pre-commercial stage, stock trading at $0.47 (down 78% YTD), and limited cash runway. Clinical execution excellence contrasts with significant financial and operational risk.

Top Insights

• REMAIN-1 Midpoint data showed Revita reduced weight regain to 4.5% vs 7.5% for sham (p=0.07), with 70% less regain in above-median GLP-1 responders
• Pivotal topline 6-month data and potential FDA PMA filing expected H2 2026; FDA De Novo feedback expected Q2 2026
• Rejuva gene therapy platform targeting long-term T2D/obesity remission through pancreatic gene delivery with first-in-human dosing potentially in H2 2026
• Company maintains $85.6M cash as of Jan 2, 2026 with runway into early 2027; CFO appointment in January 2026 signals transition to commercial-stage operations

Named Competitors

• Duodenal mucosal resurfacing devices — Competing duodenal intervention approaches
• GLP-1 agonists and analogs — Dominant pharmacological obesity treatment
• Metabolic gene therapies — Emerging gene therapy platforms for metabolic disease

Recent Developments

• (February 2026) Completed randomization in REMAIN-1 Pivotal Cohort evaluating Revita for weight maintenance after GLP-1 discontinuation
• (January 2026) Appointed Lara Smith Weber as CFO and reported $85.6M cash position with 2026 roadmap for clinical/regulatory milestones
• (January 2026) Reported positive 6-month REMAIN-1 Midpoint data showing durable weight maintenance with supportive cardiometabolic signals

Open the full interactive Fractyl Health, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.